drugset / Trial / NCT05918627

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

NCT05918627

Phase 1 Completed 32 enrolled Kadmon, a Sanofi Company
RandomizedSequentialDouble-blindBasic science

Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple doses of SLx-2119 in healthy male participants.

Timeline

Start
2009-09-21
Primary completion
2009-12-09
Completion
2009-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Belumosudil Small molecule 20 mg Oral
Subject Belumosudil Small molecule 40 mg Oral
Subject Belumosudil Small molecule 80 mg Oral
Subject Belumosudil Small molecule 160 mg Oral
Subject Belumosudil Small molecule 320 mg Oral
Subject Belumosudil Small molecule 640 mg Oral